Investor Day Lausanne, September 29, Nicholas Rolli Vice President, Investor Relations & Financial Communications

Similar documents
Designing a Smoke-Free Future

Investor Day LA&C Region Lausanne, September 29, Jeanne Pollès President, Latin America & Canada Region

Investor Day EEMA Region Lausanne, September 29, Drago Azinovic President, Eastern Europe, Middle East & Africa Region & PMI Duty Free

Investor Day EU Region Lausanne, June 26, Drago Azinovic President, European Union Region Philip Morris International

January 30, 2018 Dow Wilson President and Chief Executive Officer

Slide 1. Welcome and strategy update. Lars Fruergaard Jørgensen President and CEO

Slide 1. Welcome and introduction. Lars Rebien Sørensen President & CEO

DuPont Nutrition & Health Craig Binetti, President

ST. JUDE MEDICAL / THORATEC TRANSACTION HIGHLIGHTS July 22, 2015

JT Group Consolidated Financial Results 2018 First Quarter Results

ASCO 2018 investor event; breakout 2: Lynparza lifecycle; MRK collaboration

Morgan Stanley Global Consumer & Retail Conference New York, November 19, 2014

Welcome to the Full -Year Results Press Conference

USPSTF Draft Recommendations Investor Call. October 6, 2015

Merck Announces FDA Approval of KEYTRUDA. Provided to Investors as a Reference

Acquisition of Novartis Influenza Vaccines Business. 27 th October 2014

Slide 1. Investor presentation. London 5 February 2019

Investor Day Lausanne, September 27, 2018

Investor Day Lausanne, September 27, 2018

Slide 1. International Operations update. Mike Doustdar EVP International Operations. YASMIN FIEDLER, Germany Yasmin has type 1 diabetes

H. LUNDBECK A/S. Teleconference. 10 August PM CET. Financial results Second quarter 2011

The acquisition of Fortitech

Investor Day Lausanne, June 21, André Calantzopoulos Chief Operating Officer Philip Morris International

DIEBOLD NIXDORF AG AT GERMANY EQUITY FORUM

Slide 1. Financial update and closing remarks. Jesper Brandgaard EVP and CFO. RAFAEL DE JESÚS FLORES, Mexico Rafael has haemophilia A

Reduced-Risk Products Science Update

Memory Pharmaceuticals Establishes Plans for Clinical Program for MEM 3454 in Schizophrenia. -Broadens Roche Nicotinic Alpha-7 Alliance-

2014 CAGNY Investor Presentation. February 19, 2014

Human Nutrition Jeremy Xu President Human Nutritional & Health ROYAL DSM HEALTH NUTRITION MATERIALS

TELECONFERENCE FY February 2015

Straumann s net revenues reach CHF 185 million in Q1, driven by continuing double-digit growth in America

Remarks by André Calantzopoulos Chief Executive Officer. Jacek Olczak Chief Operating Officer. Martin King Chief Financial Officer

January 2017 Investor Presentation. confidently live life with ease

RAI reports strong 2Q16 performance and positive outlook; Accelerates returns to shareholders

Tamsulosin Hydrochloride 0.4 mg Capsule

37 th ANNUAL JP MORGAN HEALTHCARE CONFERENCE

Visionary Private Equity Group is Pleased to Announce its Investment in MEDITE Cancer Diagnostics

Patrick J. Sullivan Chief Executive Officer. January 9, 2018 Investor Presentation

Michael L. Levitz Chief Financial Officer. November 15, 2017 Investor Presentation

FORM8-K HILLENBRAND,INC.

Walgreens (WAG) Analyst: Juan Fabres Fall 2014

RAI: Strong key-brands performance delivers 2Q13 profit growth; Company reaffirms full-year EPS guidance

XXII: CTP Summarizes Scientific Case for Limiting Nicotine in Cigarettes. Company Update October 15, 2018 Industrial & Consumer Technology

Letter to Shareholders SEMI-ANNUAL REPORT 2008

1Q Fornebu, April 29, 2015 Luis Araujo and Svein Stoknes

DARA Reports Year-End 2012 Financial Results

TELECONFERENCE Q August 2015

International Operations overview and strategy. Maziar Mike Doustdar EVP International Operations. Slide 1

Cowen Investor Conference March confidently live life with ease

A world leader in allergy immunotherapy

DELICA D:5 ACTIVE GEAR 0

ADM to Acquire Neovia and Probiotics International Limited. July 2, 2018

Passion for progress, care for people

UCB announces first presentation of primary data from latest Phase 3 study evaluating brivaracetam

Nutrition Chris Goppelsroeder President & CEO DSM Nutritional Products ROYAL DSM HEALTH NUTRITION MATERIALS

Canadian Experience in Tobacco Regulations. NCDs Expert Meeting Washington, DC November 17, 2014

FY2009 First Quarter Financial Results. SUZUKI MOTOR CORPORATION August 3, 2009

RULES OF CONDUCT OF INSIDERS RESPECTING

Media Contact: Ron Rogers Investor Contact: Scott Gleason (801) (801)

Straumann reports 4% growth in local currencies (l.c.) in the first nine months of 2010

Slide 1. Winning with GLP-1. Lars Fruergaard Jørgensen President and CEO. ALEXANDRE DE GREGORIO, Brazil Alexandre has type 2 diabetes

JTI Switzerland. JTI Schweiz 3

HILLENBRAND INDUSTRIES INC

Value creation through profitable growth Danske Bank Winter Seminar 2017, Copenhagen Lars Rasmussen, President & CEO

Continued value growth

MedSurg: Endoscopy Presentation for the Investment Community at DDW. Art Butcher Senior Vice President and President, Endoscopy

ELICA 2012 Q3 RESULTS. November 14,

Merck Pipeline. October 15, 2009

AstraZeneca to Acquire Bristol- Myers Squibb Share of Global Diabetes Alliance. Becoming Global Leaders In Diabetes

Asia Illicit Tobacco Indicator 2016: Singapore. Prepared by Oxford Economics October 2017

November 2, Q Financial Results

TELECONFERENCE Q November 2015

The importance of offering adult smokers a portfolio of potentially less harmful products

Conference Call to Discuss FDA Approval of ONPATTRO (patisiran)

TOBACCO INDUSTRY MONITORING TOOL

Genomic Health. Kim Popovits, Chairman, CEO and President

Investor Presentation

2018 Bank of America Merrill Lynch Healthcare Conference

Patrick J. Sullivan, President & CEO March 7, 2016 Raymond James 37 th Annual Institutional Conference

Annual Shareholders Meeting

Industry Post-Regulation. E-Cigarette Summit Tim Phillips, ECigIntelligence. 17 th November

RAI increases 3Q13 earnings on strong operating performance; tightens full-year EPS guidance

Reynolds American to Acquire Lorillard

INVESTOR PRESENTATION

- Plans Commercial Launch of three dosing options for Excellagen in pre-filled syringes

Revolutionizing how advanced heart disease is treated

Consolidated: Financial Summary

Global Strategic Partners Merck and Pfizer Finalize Agreement to Co-Promote XALKORI (crizotinib)

Merrill Lynch Pharmaceutical, Biotechnology & Medical Device Conference New York, February 4, 2004

ObsEva Reports Third Quarter 2017 Financial Results and Provides Business Update

M (SAPPHIRE-II)

Factors influencing European cigarette markets in the short and mid term. Christoph Ihmels, ERA Packaging Conference

An exciting combination in a high growth, high margin Nutrition category. Name of chairman

ObsEva Reports Third Quarter 2018 Financial Results and Provides Business Update

WEEK OF MARCH 12, 2018 VANCOUVER, BC

Slide 1. Investor presentation. Copenhagen 1 November 2018

Q3 18 Earnings Supplemental Slides

The alcohol market is in need of a thorough review

Oral semaglutide and production expansion. Henrik Wulff EVP Product Supply. Peter Kristensen SVP Global Development

Transcription:

Investor Day Lausanne, September 29, 2016 Nicholas Rolli Vice President, Investor Relations & Financial Communications

PMI Investor Relations Mobile Application ("App") / Wi-Fi Access Free app available for download at the Apple App Store for iphone and ipad devices and at Google play for Android mobile devices ios Device Android Device 2

Forward-Looking and Cautionary Statements These presentations and related discussions contain forward-looking statements. Achievement of future results is subject to risks, uncertainties and inaccurate assumptions, and PMI is identifying important factors that, individually or in the aggregate, could cause actual results to differ materially from those contained in any forward-looking statements made by PMI PMI s business risks include: significant increases in cigarette-related taxes; the imposition of discriminatory excise tax structures; fluctuations in customer inventory levels due to increases in product taxes and prices; increasing marketing and regulatory restrictions, often with the goal of reducing or preventing the use of tobacco products; health concerns relating to the use of tobacco products and exposure to environmental tobacco smoke; litigation related to tobacco use; intense competition; the effects of global and individual country economic, regulatory and political developments; changes in adult smoker behavior; lost revenues as a result of counterfeiting, contraband and cross-border purchases; governmental investigations; unfavorable currency exchange rates and currency devaluations; adverse changes in applicable corporate tax laws; adverse changes in the cost and quality of tobacco and other agricultural products and raw materials; and the integrity of its information systems. PMI s future profitability may also be adversely affected should it be unsuccessful in its attempts to produce and commercialize products with the potential to reduce exposure to harmful constituents in smoke, individual risk and population harm; if it is unable to successfully introduce new products, promote brand equity, enter new markets or improve its margins through increased prices and productivity gains; if it is unable to expand its brand portfolio internally or through acquisitions and the development of strategic business relationships; or if it is unable to attract and retain the best global talent PMI is further subject to other risks detailed from time to time in its publicly filed documents, including the Form 10-Q for the quarter ended June 30, 2016. PMI cautions that the foregoing list of important factors is not a complete discussion of all potential risks and uncertainties. PMI does not undertake to update any forward-looking statement that it may make from time to time, except in the normal course of its public disclosure obligations Reduced-Risk Products ("RRPs") is the term we use to refer to products with the potential to reduce individual risk and population harm in comparison to smoking cigarettes 3

Reconciliations of non-gaap measures included in this presentation to the most comparable GAAP measures are provided on our website at: www.pmi.com/2016investorday/recslides Glossary of Terms: www.pmi.com/2016investorday/glossary 4

Agenda Day One THURSDAY, September 29, 2016 08:55 Nicholas Rolli Vice President, Investor Relations Welcome (Webcast Begins) 09:00 André Calantzopoulos Chief Executive Officer Presentation 09:45 Werner Barth Senior Vice President, Marketing & Sales 10:30 Coffee Break 11:00 Manuel Peitsch Chief Scientific Officer, Reduced-Risk Products 12:30 Lunch Miroslaw Zielinski President, Reduced-Risk Products Presentations and Q&A 14:00 Frederic de Wilde President, European Union Region 14:45 Drago Azinovic President, EEMA Region & PMI Duty Free 15:30 Coffee Break 16:00 Martin King President, Asia Region 16:45 Jeanne Pollès President, Latin America & Canada Region 17:30 Nicholas Rolli (Webcast Ends) Innovation Lounge Opens Note: Times are local Swiss times. Reduced-Risk Products ("RRPs") is the term the company uses to refer to products with the potential to reduce individual risk and population harm in comparison to smoking cigarettes 5

Agenda Day Two FRIDAY, September 30, 2016 08:15 Visits to the iqos Retail Lab and Brand Showroom 10:10 Nicholas Rolli Introduction (Webcast Begins) 10:15 Jacek Olczak Chief Financial Officer Presentation 10:45 Coffee Break 11:00 André Calantzopoulos Jacek Olczak Closing Q&A Session 12:00 Investor Day Concludes (Webcast Ends) Note: Times are local Swiss times. Reduced-Risk Products ("RRPs") is the term the company uses to refer to products with the potential to reduce individual risk and population harm in comparison to smoking cigarettes 6

Investor Day Lausanne, September 29, 2016